Barclays
ELOX

Barclays’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

Barclays’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-92
Closed -$6K – 4902
2021
Q3 		$6K Sell
92
-69
-43% -$4.25K ﹤0.01% 4592
2021
Q2 		$13K Sell
161
-396
-71% -$33K ﹤0.01% 4586
2021
Q1 		$74K Buy
557
+342
+159% +$52.3K ﹤0.01% 4109
2020
Q4 		$34K Sell
215
-88
-29% -$10.8K ﹤0.01% 4561
2020
Q3 		$31K Sell
303
-61
-17% -$7.31K ﹤0.01% 4793
2020
Q2 		$45K Buy
364
+155
+74% +$17.5K ﹤0.01% 4981
2020
Q1 		$16K Sell
209
-427
-67% -$69.5K ﹤0.01% 5715
2019
Q4 		$187K Buy
636
+307
+93% +$61.9K ﹤0.01% 5085
2019
Q3 		$59K Sell
329
-37
-10% -$10.5K ﹤0.01% 5823
2019
Q2 		$146K Buy
366
+177
+94% +$74.5K ﹤0.01% 5384
2019
Q1 		$88K Buy
+189
New +$91.8K ﹤0.01% 5467
2018
Q4 		– Sell
-210
Closed -$143K – 7503
2018
Q3 		$143K Buy
210
+171
+438% +$109K ﹤0.01% 5263
2018
Q2 		$27K Buy
+39
New +$25.3K ﹤0.01% 6029

Other funds holding ELOX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Barclays's ELOX Position: Q4 2021 in Review

Barclays sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q4 2021, closing a stake of 92 shares — an estimated $6K sold.

Barclays first reported a position in ELOX in Q2 2018 and held it in 13 quarters. The position peaked at $187K in Q4 2019. 38 funds tracked by Wall St. Rank hold ELOX as of Q4 2021.

  • Barclays reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 92 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $6K.
  • Barclays first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
  • Barclays's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $187K in Q4 2019.
  • 38 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.